Ovid Therapeutc (NASDAQ:OVID) has earned a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy recommendation.

Analysts have set a 1-year consensus target price of $21.00 for the company, according to Zacks. Zacks has also assigned Ovid Therapeutc an industry rank of 105 out of 265 based on the ratings given to its competitors.

Separately, Zacks Investment Research downgraded shares of Ovid Therapeutc from a “hold” rating to a “sell” rating in a research report on Wednesday, August 16th.

In other news, CEO Jeremy M. Levin acquired 15,334 shares of the company’s stock in a transaction on Friday, August 25th. The shares were bought at an average cost of $7.15 per share, with a total value of $109,638.10. Following the purchase, the chief executive officer now owns 4,601,529 shares of the company’s stock, valued at approximately $32,900,932.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. FMR LLC acquired a new position in Ovid Therapeutc in the 2nd quarter valued at $18,254,000. Jennison Associates LLC acquired a new position in Ovid Therapeutc in the 2nd quarter valued at $6,739,000. Tekla Capital Management LLC acquired a new position in Ovid Therapeutc in the 2nd quarter valued at $5,229,000. Redmile Group LLC acquired a new position in Ovid Therapeutc in the 2nd quarter valued at $4,237,000. Finally, Ameriprise Financial Inc. acquired a new position in Ovid Therapeutc in the 2nd quarter valued at $3,761,000. 32.44% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This story was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/10/04/zacks-ovid-therapeutc-ovid-given-21-00-consensus-target-price-by-analysts.html.

Shares of Ovid Therapeutc (OVID) traded down 0.35% on Wednesday, reaching $8.61. 62,376 shares of the company’s stock were exchanged. Ovid Therapeutc has a one year low of $5.28 and a one year high of $15.93. The firm has a 50 day moving average of $8.28 and a 200 day moving average of $10.12. The firm’s market capitalization is $211.82 million.

Ovid Therapeutc (NASDAQ:OVID) last issued its quarterly earnings data on Thursday, August 10th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.09). On average, equities research analysts predict that Ovid Therapeutc will post ($3.88) EPS for the current year.

Ovid Therapeutc Company Profile

Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.

Get a free copy of the Zacks research report on Ovid Therapeutc (OVID)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ovid Therapeutc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutc and related companies with MarketBeat.com's FREE daily email newsletter.